Story · Medicine & Biotech

Lilly adds to buyout streak with $1.5B purchase of startup Calytrix

3 outlets · first reported by BioPharma Dive on · latest · 3 countries

Lilly’s 15th announced company acquisition this year — by far the most in the biopharmaceutical sector — centers around a precision therapy for rare blood disorders known as myeloproliferative neoplasms. (BioPharma Dive)

Coverage, in order

  1. first BioPharma Dive indie
    Lilly adds to buyout streak with $1.5B purchase of startup Calytrix

    Lilly’s 15th announced company acquisition this year — by far the most in the biopharmaceutical sector — centers around a precision therapy for rare blood disorders known as myeloproliferative neoplasms.

  2. Iatronet Greece indie el
    Lilly buys Calytrix Bio for $1.5 billionΗ Lilly αγοράζει την Calytrix Bio για και 1,5 δισεκατομμύριο δολάρια

    The deal is expected to strengthen Lilly's presence in the field.Η συμφωνία αναμένεται να ενισχύσει την παρουσία της Lilly στην αιματολογία.

  3. Pharmaphorum UK indie
    Lilly strikes again, buying Calytrix in $1.5bn deal

    Lilly strikes again, buying Calytrix in $1.5bn deal Phil.Taylor Mon, 16/11/2026 - 13:35

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.